Physician profile
Asha Thomas
NPI 1124171459
$931.11
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.69 · 2020: $140 · 2021: $407 · 2022: $222 · 2023: $108 · 2024: $21.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $129.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $354.76 | 2021-2024 | Ozempic, Rybelsus |
| Amgen INC. | $161.56 | 2020-2022 | |
| Horizon Therapeutics Plc | $127.18 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $94.73 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $62.46 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $31.10 | 2019-2021 | |
| Boston Scientific Corporation | $22.37 | 2023 | Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.51 | 2021 | |
| Medtronic USA, INC. | $18.09 | 2019 | |
| Medtronic, INC. | $16.28 | 2023 | Ligasure |
| Alexion Pharmaceuticals, INC. | $14.07 | 2023 | Strensiq |
| Bardy Diagnostics, INC. | $7.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asha Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.